Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using Aflibercept

2022-09-004

The purpose of the present study was to evaluate the outcomes of type 1 macular neovascularization (MNV), including polypoidal choroidal vasculopathy in patients treated tolerating subretinal fluid (SRF) using Aflibercept in a clinical setting. Approximately 150 patients are anticipated to be enrolled in this study. SRF is a primary type of fluid compartment prevalent in type 1 aneurysmal MNV. In a recent study, the prevalence of SRF during 24-month follow-up period was 36.7% to 38.8% in type 1 MNV and polypoidal choroidal vasculopathy (PCV), 20.0% in type 2 MNV, and 7.7% in type 3 MNV. In addition, patients with SRF showed better visual prognosis in type 1 MNV/PCV. For this reason, type 1 MNV is an appropriate candidate for evaluating the influence of tolerating SRF.

2022-12-05

2023-05-31

2023-11-30

Completed

135

Inclusion Criteria: * Patient who were diagnosed with type 1 MNV or PCV * Patients who were treated using aflibercept between January 2021 and December 2022 * Patients underwent continuous aflibercept injections with tolerating subfoveal retinal fluid more than 6 months. Exclusion Criteria: * Less than 6 months of tolerating-fluid phase * Patients without indocyanine green angiography (ICGA) result * Patients who received other treatment for neovascular age-related macular degeneration (AMD), except for aflibercept (eg. ranibizumab, bevacizumab, or PDT) * History of intraocular or periocular steroid injection * History of vitreoretinal surgery or glaucoma surgery * History of intraocular inflammation * Uncontrolled glaucoma (IOP ≥ 25mmHg)

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'CASE_ONLY', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 135, 'type': 'ACTUAL'}}

2023-12-14